Prescribing information

 

Explore two analyses from BADBIR.

Latest analysis by the BADBIR group

See the independent publication which supports the position of Cosentyx as a first-line biologic in moderate to severe plaque psoriasis.1

This link will take you to the Wiley Online Library website, which is a non-Novartis website.

View the publication

 

Analysis by Novartis using BADBIR data

See the Cosentyx data below demonstrating long-term effectiveness and drug survival.2

Watch now: a 2-minute summary of this data
 

Click here for Cosentyx (secukinumab) prescribing information

About the analysis by Novartis using BADBIR data

BADBIR evaluates the long-term safety and effectiveness of biologic treatments for psoriasis in the UK and ROI.2,3

Icon of a clipboard

What is BADBIR?

BADBIR is a prospective, longitudinal pharmacovigilance register assessing the long-term safety of biologics, conventional systemic therapies and small molecule immunomodulators for psoriasis.

 

Icon of a calendar

Observation period

  • Adults enrolled from 01 January 2016 to 31 August 2018 (still ongoing)
  • Only patients with at least one follow-up visit were included
 

 Icon of people

Patient population

1679 moderate to severe psoriasis patients treated with the licensed dose of Cosentyx. Of these:

  • ~1/3 biologic-naïve patients (n=507)
  • ~2/3 biologic-exposed patients (n=1172)

 

 

The results

Infographic showing the proportion of biologic-naïve patients in the analysis achieving aPASI less than or equal to 3 over 1 and 2 years.

*Analysis by Novartis using BADBIR data. aPASI ≤3 reflects clear or almost clear skin, or a physician global assessment of 0/1.4

aPASI scores at 12 and 24 months were imputed using data recorded ±90 days of each time point. The fall in patient numbers between Years 1 and 2 reflects fewer patients being on treatment long enough to reach the 2-year time point.2

Line graph showing drug survival rates in the analysis over 2 years

Adapted from Bewley A et al. 2019.2

Adult patients with moderate to severe plaque psoriasis treated with Cosentyx 300 mg enrolled from 01 January 2016 to 31 August 2018 with at least one follow-up visit evaluated were included in this Novartis analysis of the BADBIR registry. The n-numbers reflect those patients meeting each time point. BADBIR approved the statistical analysis plan used.2

aPASI, absolute Psoriasis Area Severity Index; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; DMARD, disease-modifying anti-rheumatic drug; MTX, methotrexate; ROI, Republic of Ireland.

References

  1. Yiu ZZN et al. Br J Dermatol 2020; doi:10.1111/bjd.18981.
  2. Bewley A et al. Secukinumab 300 mg demonstrates high and sustained effectiveness in treating patients with moderate to severe plaque psoriasis: Real world evidence from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Poster presented at: the 6th Annual Practical Symposium; 8–11 August 2019; Beaver Creek, Colorado, USA.
  3. Burden AD et al. Br J Dermatol 2012;166(3):545–554.
  4. Amatore F et al. J Eur Acad Dermatol Venereol 2019;33:464–483.
COS20-C008a May 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]